Connect Biopharma Holdings Limited
CNTB
$2.05
-$0.10-4.65%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -82.31% | 66.34% | 72.43% | 72.06% | 72.09% |
| Total Depreciation and Amortization | -2.04% | -17.68% | -29.17% | -41.25% | -49.76% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2.74% | 66.63% | 117.71% | 34.53% | -11.05% |
| Change in Net Operating Assets | 120.76% | -230.53% | -258.07% | -338.29% | -881.18% |
| Cash from Operations | -53.54% | -1.64% | 49.89% | 62.68% | 70.31% |
| Capital Expenditure | -751.22% | -1,178.74% | -645.68% | 78.15% | 97.34% |
| Sale of Property, Plant, and Equipment | 0.00% | 0.00% | -- | 0.00% | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -157.16% | -148.38% | -103.55% | -47.77% | 153.50% |
| Cash from Investing | -158.55% | -149.35% | -104.36% | -46.75% | 196.49% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 2.78% | 105.56% | -- | 200.97% | 149.59% |
| Issuance of Common Stock | 100.00% | 629.41% | 446.67% | 314.01% | 183.46% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 51.39% | 273.58% | 775.56% | 449.74% | 220.25% |
| Foreign Exchange rate Adjustments | 56.63% | 51.98% | -9.86% | 91.26% | 95.99% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -344.58% | -296.08% | -202.64% | 101.76% | 136.33% |